文献速递重症综合管理与镇静镇痛

重症患者肌肉肌肉生长抑制素基因表达与血浆浓度降低

Muscular myostatin gene expression and plasma concentrations are decreased in critically ill patients.
PubMed 文献 · Crit Care · 2022-08-03
一句话结论重症患者肌肉MSTN基因表达和血浆肌肉生长抑制素均下调,ICUAW者基因表达更低,提示治疗性抑制肌肉生长抑制素可能缺乏病理生理依据。

该研究为两项前瞻性研究汇总数据的回顾性分析,评估重症患者肌肉肌肉生长抑制素(myostatin)血浆浓度(第4、8、14天)和骨骼肌MSTN基因表达(第15天)的动态变化及其与临床、电生理结局、肌肉代谢和萎缩通路的关系。结果显示,与健康对照相比,重症患者MSTN基因表达(中位[IQR]倍数变化:1.00 [0.68-1.54] vs. 0.26 [0.11-0.80];p=0.004)和血浆肌肉生长抑制素浓度均显著降低;重症患者血浆肌肉生长抑制素随时间升高(第4天:0.13 [0.08/0.21] vs. 第8天:0.23 [0.10/0.43] vs. 第14天:0.40 [0.26/0.61];p<0.001)。合并ICUAW者较无ICUAW者MSTN基因表达显著更低(0.17 [0.10/0.33] vs. 0.51 [0.20/0.86];p=0.047)。肌肉生长抑制素水平与肌力(相关系数0.339;p=0.020)和胰岛素敏感指数(相关系数0.357;p=0.015)直接相关。未观察到血浆肌肉生长抑制素浓度及MSTN表达水平与动员水平、电生理变量或萎缩通路标志物之间的关联。作者认为,先前提出的治疗性抑制肌肉生长抑制素似乎缺乏改善重症患者肌肉质量的病理生理依据。

要点

  • 重症患者骨骼肌MSTN基因表达较健康对照显著降低(中位[IQR]倍数变化:1.00 [0.68-1.54] vs. 0.26 [0.11-0.80];p=0.004)。
  • 重症患者血浆肌肉生长抑制素浓度随时间升高:第4天0.13 [0.08/0.21] vs. 第8天0.23 [0.10/0.43] vs. 第14天0.40 [0.26/0.61];p<0.001。
  • 合并ICUAW者较无ICUAW者MSTN基因表达显著更低(0.17 [0.10/0.33] vs. 0.51 [0.20/0.86];p=0.047)。
  • 肌肉生长抑制素水平与肌力(相关系数0.339;p=0.020)和胰岛素敏感指数(相关系数0.357;p=0.015)直接相关。
  • 作者认为,先前提出的治疗性抑制肌肉生长抑制素似乎缺乏改善重症患者肌肉质量的病理生理依据。

适用人群与场景

  • 重症患者,来自两项前瞻性研究的汇总数据;与健康对照比较。
  • 按是否合并ICUAW分组比较MSTN基因表达水平。

研究设计与关键结果

  • 研究类型:两项前瞻性研究汇总数据的回顾性分析。
  • 评估重症患者肌肉生长抑制素血浆浓度(第4、8、14天)和骨骼肌MSTN基因表达(第15天)的动态变化。
  • 与健康对照相比,重症患者MSTN基因表达(中位[IQR]倍数变化:1.00 [0.68-1.54] vs. 0.26 [0.11-0.80];p=0.004)和血浆肌肉生长抑制素浓度均显著降低。
  • 重症患者血浆肌肉生长抑制素随时间升高(中位[IQR]倍数变化:第4天0.13 [0.08/0.21] vs. 第8天0.23 [0.10/0.43] vs. 第14天0.40 [0.26/0.61];p<0.001)。
  • 合并ICUAW者较无ICUAW者MSTN基因表达显著更低(中位[IQR]倍数变化:0.17 [0.10/0.33] vs. 0.51 [0.20/0.86];p=0.047)。
  • 肌肉生长抑制素水平与肌力直接相关(相关系数0.339;p=0.020),与胰岛素敏感指数直接相关(相关系数0.357;p=0.015)。
  • 未观察到血浆肌肉生长抑制素浓度及MSTN表达水平与动员水平、电生理变量或萎缩通路标志物之间的关联。

证据类型、等级与局限

  • 证据类型:两项前瞻性研究汇总数据的回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,先前提出的治疗性抑制肌肉生长抑制素似乎缺乏改善重症患者肌肉质量的病理生理依据。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The objective was to investigate the role of gene expression and plasma levels of the muscular protein myostatin in intensive care unit-acquired weakness (ICUAW). This was performed to evaluate a potential clinical and/or pathophysiological rationale of therapeutic myostatin inhibition.

METHODS: A retrospective analysis from pooled data of two prospective studies to assess the dynamics of myostatin plasma concentrations (day 4, 8 and 14) and myostatin gene (MSTN) expression levels in skeletal muscle (day 15) was performed. Associations of myostatin to clinical and electrophysiological outcomes, muscular metabolism and muscular atrophy pathways were investigated.

RESULTS: MSTN gene expression (median [IQR] fold change: 1.00 [0.68-1.54] vs. 0.26 [0.11-0.80]; p = 0.004) and myostatin plasma concentrations were significantly reduced in all critically ill patients when compared to healthy controls. In critically ill patients, myostatin plasma concentrations increased over time (median [IQR] fold change: day 4: 0.13 [0.08/0.21] vs. day 8: 0.23 [0.10/0.43] vs. day 14: 0.40 [0.26/0.61]; p < 0.001). Patients with ICUAW versus without ICUAW showed significantly lower MSTN gene expression levels (median [IQR] fold change: 0.17 [0.10/0.33] and 0.51 [0.20/0.86]; p = 0.047). Myostatin levels were directly correlated with muscle strength (correlation coefficient 0.339; p = 0.020) and insulin sensitivity index (correlation coefficient 0.357; p = 0.015). No association was observed between myostatin plasma concentrations as well as MSTN expression levels and levels of mobilization, electrophysiological variables, or markers of atrophy pathways.

CONCLUSION: Muscular gene expression and systemic protein levels of myostatin are downregulated during critical illness. The previously proposed therapeutic inhibition of myostatin does therefore not seem to have a pathophysiological rationale to improve muscle quality in critically ill patients.

TRIAL REGISTRATION: ISRCTN77569430 -13th of February 2008 and ISRCTN19392591 17th of February 2011.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Grunow JJ, Reiher K, Carbon NM, et al. Muscular myostatin gene expression and plasma concentrations are decreased in critically ill patients. Crit Care. 2022. PMID: 35922829. doi:10.1186/s13054-022-04101-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。